PRESCIENT THERAPEUTICS
Prescient Therapeutics (PTX) is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of solid and hematological cancers.
PRESCIENT THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
1999-01-01
Address:
Melbourne, Victoria, Australia
Country:
Australia
Website Url:
http://www.prescienttherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+61396927222
Email Addresses:
[email protected]
Total Funding:
3 M USD
Technology used in webpage:
SPF Amazon Amazon Ohio Region NameBright
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.prescienttherapeutics.com
- Host name: ec2-54-209-32-212.compute-1.amazonaws.com
- IP address: 54.209.32.212
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Prescient Therapeutics" on Search Engine
Prescient Therapeutics - Wikipedia
Prescient Therapeutics Ltd is a clinical stage oncology company. The company is focused on the development of a universal CAR-T platform (OmniCAR), enhanced CAR-T cell manufacturing & function (CellPryme) and on two small molecule drug targeted therapies (PTX-100 & PTX-200).See details»
Prescient Therapeutics - Crunchbase Company Profile
Company Type For Profit. Contact Email [email protected]. Phone Number +61396927222. Prescient Therapeutics (PTX) is a clinical stage oncology company …See details»
Prescient Therapeutics | LinkedIn
About us. Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular …See details»
Investor Centre - PTX Therapeutics
Mar 25, 2024 About Prescient Therapeutics. Prescient Therapeutics develops personalised therapies to conquer cancer. It has a broad portfolio of well advanced …See details»
Prescient Therapeutics - PTX Therapeutics
Prescient Therapeutics (ASX: PTX) Tuesday, 4th October 12pm (AEDT) Please join Prescient CEO and managing director Steven Yatomi-Clarke for an investor briefing. In …See details»
Prescient Therapeutics hopes to accelerate bid for US …
Mar 21, 2023 Prescient Therapeutics (ASX:PTX) will seek approval from the US Food and Drug Administration (FDA) for an accelerated approval study after its Phase 1b clinical trial of PTX-100 in relapsed and …See details»
Prescient Therapeutics Ltd, PTX:ASX summary - FT.com
PTX:ASX. Actions. Health Care Pharmaceuticals and Biotechnology. Price (AUD) 0.045. Today's Change -0.001 / -2.17% Shares traded 580.84k. 1 Year change -44.44% Beta …See details»
News & media - PTX Therapeutics
Mar 7, 2024 Prescient Therapeutics (ASX: PTX) advances PTX-100 to pivotal Phase 2 study. January 10, 2024. Proactive Investors.See details»
Here's Why We're Not Too Worried About Prescient …
Sep 28, 2023 When Prescient Therapeutics last reported its balance sheet in June 2023, it had zero debt and cash worth AU$22m. Importantly, its cash burn was AU$6.2m over …See details»
Prescient Therapeutics Ltd (PTX) Stock Price & News - Google
Get the latest Prescient Therapeutics Ltd (PTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …See details»
Prescient Therapeutics - Contacts, Employees, Board Members, …
Prescient Therapeutics. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 4. Contacts 5. About. …See details»
Prescient Therapeutics - Funding, Financials, Valuation & Investors
Prescient Therapeutics is a biopharmaceutical company, discovers and develops novel immunotherapeutic products for the treatment of chronic.See details»
Investor Centre - PTX Therapeutics
Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cell therapies. CONTACT. P: +61 …See details»
Organization | Prescient Therapeutics, Ltd. - CDEK
Prescient Therapeutics, Ltd. Report issue. For profit Phase 1 Phase 2. Founded: Melbourne Australia (1987 ... Organization Overview. First Clinical Trial. 2002 …See details»
Prescient Therapeutics Share Purchase Plan - PTX Therapeutics
Prescient Therapeutics Limited (ASX: PTX) has launched a Share Purchase Plan (SPP) targeting to raise $8,000,000 at $0.175/share, representing a discount of approximately …See details»
Share Price and Announcements - PTX Therapeutics
Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cell therapies. CONTACT P: +61 …See details»
Prescient Therapeutics - Crunchbase
Prescient Therapeutics is a biopharmaceutical company, discovers and develops novel immunotherapeutic products for the treatment of chronic.See details»
Prescient Therapeutics - Tech Stack, Apps, Patents & Trademarks
Prescient Therapeutics is a biopharmaceutical company, discovers and develops novel immunotherapeutic products for the treatment of chronic.See details»